# Investigating the Role of p21-Highly Expressing Senescent Cells in Alzheimer's Dementia

> **NIH NIH F30** · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · 2023 · $43,216

## Abstract

PROJECT SUMMARY/ABSTRACT
Alzheimer’s Dementia (AD) is a leading cause of morbidity and mortality that is incompletely understood and
lacking effective treatment. Accumulation of senescent cells (SnCs) has recently been implicated in AD
pathogenesis and targeted removal of these cells may offer new therapeutic avenues. Cellular senescence is a
cell fate defined by stable proliferative arrest, apoptotic resistance, and production of a pro-inflammatory
secretome. Though senescence programming can contribute to proper development and regenerative
processes, its dysregulation is increasingly linked with disease burden and pathology, including AD. While SnC
modulation and clearance is a promising therapeutic target, it is increasingly clear that these cells are highly
heterogeneous in their characteristics and function. We recently developed a mouse model to characterize a
unique population of SnCs that highly express the cell cycle blockade protein p21 (p21high cells) and
demonstrated that these cells play a causal role in age related physical dysfunction and metabolic disease.
Furthermore, other literature has implicated clearance of pan-SnCs, which include p21high subpopulations, with
cognitive improvements in AD. However, it is unknown if p21high cells make distinct contributions to AD or if their
targeted removal can further counteract AD pathology. Therefore, this proposal aims to investigate the specific
contributions of p21high SnCs to AD. Preliminary experiments have demonstrated that p21high cells accumulate in
the brain of mouse AD models featuring amyloid- β plaque. However, it is unknown when these cells begin to
accumulate in relation to the underlying disease process and what cell types are undergoing senescence.
Therefore, in Aim 1, we will define the precise timeline of p21high cell accumulation in relation to amyloid- β plaque
deposition (1A) and determine what cell types these represent (1B) by tracking these cells with a transgenic
fluorescence reporter system and immunohistochemistry. To understand if these p21high SnCs play a causal role
in AD, in Aim 2 we propose to selectively eliminate these cells via an inducible suicide gene to determine if
targeted removal of these cells can either prevent (2A) or alleviate (2B) AD associated amyloid- β plaque
formation and impaired performance on cognitive assays. We will also conduct single nuclei RNA sequencing
(2C) on brains with or without p21high cell elimination to assess for changes in AD associated neuro-inflammatory
pathways and explore underlying disease mechanisms associated with p21high cells. These aims will help to
define the role of p21high SnCs in AD and may serve as a basis for new targeted disease modulating therapy.
Furthermore, these results will further implicate p21high cells in age related disease and broaden the field’s
appreciation of SnC heterogeneity. This work is part of a tailored career development plan at UConn Health that
integrates training in aging biology,...

## Key facts

- **NIH application ID:** 10606953
- **Project number:** 1F30AG081092-01
- **Recipient organization:** UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
- **Principal Investigator:** Nathan Gasek
- **Activity code:** F30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $43,216
- **Award type:** 1
- **Project period:** 2023-04-15 → 2027-04-14

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10606953

## Citation

> US National Institutes of Health, RePORTER application 10606953, Investigating the Role of p21-Highly Expressing Senescent Cells in Alzheimer's Dementia (1F30AG081092-01). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10606953. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*